<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6231">
  <stage>Registered</stage>
  <submitdate>15/12/2016</submitdate>
  <approvaldate>15/12/2016</approvaldate>
  <nctid>NCT03003962</nctid>
  <trial_identification>
    <studytitle>A Study of Durvalumab Versus Standard of Care in Advanced Non Small-Cell Lung Cancer</studytitle>
    <scientifictitle>A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>D419AC00002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non Small Cell Lung Carcinoma NSCLC</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Durvalumab (MEDI4736)
Treatment: drugs - Paclitaxel + carboplatin
Treatment: drugs - Gemcitabine + cisplatin
Treatment: drugs - Gemcitabine + carboplatin
Treatment: drugs - Pemetrexed + cisplatin
Treatment: drugs - Pemetrexed + carboplatin

Experimental: Durvalumab - PD-L1 monoclonal Antibody monotherapy

Active Comparator: Standard of Care - Standard of Care Platinum-Based chemotherapy


Other interventions: Durvalumab (MEDI4736)
PD-L1 monoclonal Antibody

Treatment: drugs: Paclitaxel + carboplatin
Chemotherapy Agents

Treatment: drugs: Gemcitabine + cisplatin
Chemotherapy Agents

Treatment: drugs: Gemcitabine + carboplatin
Chemotherapy Agents

Treatment: drugs: Pemetrexed + cisplatin
Chemotherapy Agent

Treatment: drugs: Pemetrexed + carboplatin
Chemotherapy Agent

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The efficacy of Durvalumab therapy compared to SoC in terms of progression-free survival (PFS) in patients with NSCLC</outcome>
      <timepoint>3 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The efficacy of Durvalumab therapy compared to SoC in terms of Overall Survival (OS) in patients with NSCLC</outcome>
      <timepoint>3 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The efficacy of Durvalumab compared to SoC in terms of Objective response rate (ORR)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The efficacy of Durvalumab compared to SoC in terms of Duration of response (DoR)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The efficacy of Durvalumab compared to SoC in terms of A Proportion of patients alive and progression free at 12 months from randomization (APF12)</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The efficacy of Durvalumab compared to SoC in terms of Progression-free survival after subsequent anticancer therapy (PFS2)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease-related symptoms in subjects treated with durvalumab compared to SoC using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-LC13)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health-related quality of life in subjects treated with durvalumab compared to SoC using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The immunogenicity of durvalumab by measuring the presence of Anti-drug Antibodies</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          -  Aged at least 18 years

          -  Documented evidence of Stage IV NSCLC

          -  No sensitizing EGFR mutation and ALK rearrangement

          -  PD-L1 expression at least 25%

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>130</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior chemotherapy or any other systemic therapy for advanced NSCLC

          -  Prior exposure to immune-mediated therapy, including, but not limited to, other
             anti-cytotoxic T- lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell
             death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies,
             excluding therapeutic anticancer vaccines

          -  Brain metastases or spinal cord compression unless the patient is stable and off
             steroids for at least 14 days prior to start of study treatment

          -  Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant

          -  Active or prior documented autoimmune or inflammatory disorders (e.g., colitis or
             Crohn's disease]</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>2/01/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>440</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>12/06/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - Box Hill</hospital>
    <hospital>Research Site - Gosford</hospital>
    <hospital>Research Site - Kogarah</hospital>
    <hospital>Research Site - Melbourne</hospital>
    <hospital>Research Site - St Leonards</hospital>
    <postcode>3128 - Box Hill</postcode>
    <postcode>2250 - Gosford</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>3000 - Melbourne</postcode>
    <postcode>2065 - St Leonards</postcode>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Bengbu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Changchun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Changsha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Chengdu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Chongqing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Chongqin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Haikou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Hangzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Harbin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Jinan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Linhai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Nanchang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Nanjing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Ningbo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shenyang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shijiazhuang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Urumqi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Wanzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Wenzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Wuhan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Xi'an</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Zhengzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Zhuhai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Cheongju-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Jinju-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Omsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg,</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Yaroslavl</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chom Thon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Songkla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Vietnam</country>
      <state>Can Tho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Vietnam</country>
      <state>Hanoi city</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Vietnam</country>
      <state>Hanoi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Vietnam</country>
      <state>Ho Chi Minh</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomized, open-label, multi-center Phase III study to determine the efficacy and
      safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of
      advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic
      lymphoma kinase (ALK) wild-type and with PD-L1-high expression</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03003962</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>AstraZeneca Clinical Study Information Center</name>
      <address />
      <phone>1-877-240-9479</phone>
      <fax />
      <email>information.center@astrazeneca.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>